| Archives |
|
| Link to corporate news at Roche.com |
|
| FUZEON and Roche in HIV: Notes to Editors
|
|
|
|
| Press releases |
|
|
 |
UNICEF AND ROCHE ANNOUNCE PARTNERSHIP TO IMPROVE THE LIVES OF CHILDREN ORPHANED BY AIDS IN AFRICA
12-Oct-06 |
|
|
FUZEON COMBINED WITH NEW INVESTIGATIONAL HIV DRUG RESULTS IN REMARKABLY HIGH NUMBER OF HIV PATIENTS ACHIEVING UNDETECTABLE VIRAL LOAD
05-Oct-06 |
|
|
FIRST TECHNOLOGY TRANSFERS FROM ROCHE TO ENABLE LOCAL PRODUCTION OF HIV MEDICINE FOR AFRICA
20-Sep-06 |
|
|
UPDATED INTERNATIONAL AIDS SOCIETY GUIDELINES RECOMMEND NEW GOAL OF UNDETECTABLE VIRAL LOAD FOR TREATMENT-EXPERIENCED PATIENTS
17-Aug-06 |
|
|
WORLD�S FIRST APPROVAL OF NEW HIV DRUG TMC114 PROVIDES POTENT NEW TREATMENT OPTION WITH FUZEON MAKING GOAL OF �UNDETECTABLE� MORE ACHIEVABLE FOR PATIENTS LIVING WITH DRUG RESISTANT HIV
23-Jun-06 |
|
|
CAMBODIA TREATMENT PROGRAMME ENROLS OVER 1000 HIV/AIDS PATIENTS
03-May-06 |
|
|
ROCHE AND TRIMERIS ANNOUNCE SELECTION OF TWO NEXT GENERATION HIV FUSION INHIBITOR DRUG CANDIDATES FOR DEVELOPMENT
19-Jan-06 |
|
|
ROCHE OFFERS HELP TO LOCAL MANUFACTURERS TO PRODUCE HIV MEDICINE FOR SUB-SAHARAN AFRICA AND LEAST DEVELOPED COUNTRIES
12-Jan-06 |
|
|
INVESTIGATIONAL BOOSTED PROTEASE INHIBITOR, TMC114, WORKS BETTER IN COMBINATION WITH FUZEON�
20-Dec-05 |
|
|
ROCHE HIV/AIDS CLINICAL TRIALS POLICY IN LOW AND MIDDLE INCOME DEVELOPING COUNTRIES
15-Dec-05 |
|
|
FOOD, CLOTHING AND EDUCATION FOR AIDS ORPHANS IN MALAWI
01-Dec-05 |
|
|
NEW EUROPEAN HIV TREATMENT GUIDELINES RECOMMEND BOOSTED INVIRASE� AS A FIRST CHOICE TREATMENT FOR PATIENTS STARTING THERAPY
18-Nov-05 |
|
|
NEW STUDY SHOWS PATIENTS MORE WILLING TO CONSIDER SELF-INJECTABLE HIV THERAPY THAN MANY PHYSICIANS ANTICIPATE
18-Nov-05 |
|
|
EACS MEDIA BREAKFAST: CAN LATEST ADVANCES IN HEALTH PSYCHOLOGY HELP IMPROVE HIV CARE?
11-Nov-05 |
|
|
TIPRANAVIR'S EU APPROVAL PROVIDES A NEW ACTIVE DRUG TO BE COMBINED WITH FUZEON� FOR HIV PATIENTS FACING RESISTANCE
26-Oct-05 |
|
|
INFLUENTIAL HIV/AIDS TREATMENT GUIDELINES SUPPORT USE OF FUZEON� PLUS AN ACTIVE BOOSTED PROTEASE INHIBITOR FOR TREATMENT-EXPERIENCED PATIENTS
14-Oct-05 |
|
|
NEWEST HIV DRUGS SHOULD BE USED WITH FUZEON� - GIVING PATIENTS FACING HIV RESISTANCE THEIR BEST CHANCE TO ACHIEVE UNDETECTABLE VIRAL LOADS
27-Jul-05 |
|
|
PATIENTS TREATED WITH BOOSTED INVIRASE, A POTENT ANTI-HIV TREATMENT, SHOWED NO SIGNIFICANT RESISTANCE TO PROTEASE INHIBITORS
25-Jul-05 |
|
|
ESTIMATED NUMBER OF PEOPLE LIVING WITH HIV IN DEVELOPING COUNTRIES RECEIVING ANTIRETROVIRAL (ARV) TREATMENT WITH MEDICINES PROVIDED BY THE AAI AS OF MARCH 2005
14-Jul-05 |
|
|
EUROPEAN APPROVAL FOR ROCHE'S NEW INVIRASE 500 MG TABLET FOR THE TREATMENT OF HIV
27-May-05 |
|
|
NEW EUROPEAN CONSENSUS GUIDELINES RECOGNISE PEGYLATED INTERFERON COMBINATION THERAPY AS STANDARD OF CARE FOR PATIENTS WITH HIV-HCV CO-INFECTION
07-Mar-05 |
|
|
US APPROVES PEGASYS AND COPEGUS AS FIRST HEPATITIS C TREATMENT FOR HIV PATIENTS
28-Feb-05 |
|
|
ROCHE�S NEW INVIRASE 500 MG HIV TREATMENT RECEIVES POSITIVE OPINION FROM EUROPEAN AUTHORITIES
21-Feb-05 |
|
|
PEGASYS� COMBINATION THERAPY APPROVED FOR THE TREATMENT OF HEPATITIS C AND HIV CO-INFECTION IN EUROPE
03-Feb-05 |
|
|
NEW DATA SHOW MORE THAN 333,000 HIV PATIENTS IN THE DEVELOPING WORLD ARE BEING TREATED BY MEDICINES SUPPLIED BY THE ACCELERATING ACCESS INITIATIVE (AAI) COMPANIES
25-Jan-05 |
|
|
ROCHE AIDS WALK: EMPLOYEES� INITIATIVE HELPS CHILDREN AFFECTED BY HIV/AIDS
22-Dec-04 |
|
|
ROCHE'S NEW INVIRASE 500 MG RECEIVES APPROVAL IN US AFTER PRIORITY REVIEW BY FDA
20-Dec-04 |
|
|
ROCHE EMPLOYEES AT ALMOST 60 SITES WORLDWIDE PARTICIPATE IN THE ROCHE AIDS WALK TO SUPPORT CHILDREN ORPHANED BY HIV/AIDS
30-Nov-04 |
|
|
OPENING OF NEW HIV CENTRE IN CAMBODIA SIGNIFIES FURTHER PROGRESS IN EFFORTS TO TACKLE HIV/AIDS
15-Nov-04 |
|
|
PRIX GALIEN SPEECH BY MAX BUCHER
08-Oct-04 |
|
|
INTERNATIONAL PRIX GALIEN 2004: REVOLUTIONARY HIV DRUG FUZEON RECEIVES MOST PRESTIGIOUS AWARD FOR INNOVATION IN PHARMACEUTICAL INDUSTRY
08-Oct-04 |
|
|
GROUND-BREAKING PEGASYS� TRIAL IN HIV�HCV CO-INFECTED PATIENTS PUBLISHED IN NEW ENGLAND JOURNAL OF MEDICINE
29-Jul-04 |
|
|
4 OUT OF 5 ELIGIBLE PATIENTS MISSING OPPORTUNITY TO BENEFIT FROM LATEST HIV BREAKTHROUGH
12-Jul-04 |
|
|
UNIQUE STUDY DEMONSTRATES SUCCESS RATES OF HAART IN PEOPLE WITH HIV/AIDS IN AFRICA
11-Jul-04 |
|
|
ROCHE FILES NEW INVIRASE� 500 MG FORMULATION IN USA - FILING IN EUROPE TO FOLLOW WITHIN DAYS
22-Jun-04 |
|
|
ROCHE FURTHER REDUCES PRICES OF HIV PROTEASE INHIBITOR MEDICINES FOR LOW AND LOWER MIDDLE INCOME COUNTRIES
08-Jun-04 |
|
|
SIGNIFICANT BENEFITS OF FUZEON FOR WIDE RANGE OF PRE-TREATED HIV/AIDS PATIENTS
17-May-04 |
|
|
PEGASYS� AND COPEGUS� NOW OFFERS BENEFITS IN A WIDER RANGE OF HEPATITIS C PATIENTS
15-Apr-04 |
|
|
PEGASYS� AND COPEGUS� ACHIEVE HIGHEST SUSTAINED VIROLOGICAL RESPONSE EVER ACHIEVED IN HIV�HCV CO-INFECTED PATIENTS
12-Feb-04 |
|
|
DATA SHOWS FUZEON DOES NOT INCREASE LIPODYSTROPHY IN PRE-TREATED HIV PATIENTS
12-Feb-04 |
|
|
VIRACEPT RECEIVES POSITIVE OPINION IN EUROPE FOR NEW CONVENIENT 625MG FORMULATION
23-Jan-04 |
|
|
ROCHE CHOSEN BY WILLIAM J CLINTON PRESIDENTIAL FOUNDATION TO SUPPORT HIV/AIDS INITIATIVE - AN ADDITIONAL COMPONENT IN ROCHE'S GLOBAL EFFORT TO PROVIDE HEALTHCARE FOR PEOPLE IN AREAS WHERE ACCESS IS LIMITED
15-Jan-04 |
|
|
FOLLOWING THE SUCCESSFUL DEVELOPMENT OF FUZEON ROCHE AND TRIMERIS SIGN NEW RESEARCH AGREEMENT TO DEVELOP NEXT GENERATION HIV FUSION INHIBITORS
06-Jan-04 |
|
|
EASTERN EUROPE URGED TO PREPARE NOW FOR GROWING THREAT OF HIV RESISTANCE
27-Oct-03 |
|
|
NEW PARTNERSHIP BETWEEN GOVERNMENT, INDUSTRY AND ACADEMIA TO EXPAND ACCESS TO HIV TREATMENT IN CAMBODIA
16-Sep-03 |
|
|
FUZEON - DELIVERING AN INNOVATIVE SOLUTION FOR TODAY AND TOMORROW
15-Sep-03 |
|
|
FUZEON - A REVOLUTION IN HIV CARE
15-Jul-03 |
|
|
FUZEON PRESS BRIEFING
02-Jul-03 |
|
|
THE NEW ENGLAND JOURNAL OF MEDICINE FEATURES BACK-TO-BACK ARTICLES ON FUZEON, A REVOLUTIONARY HIV TREATMENT
29-May-03 |
|
|
EUROPEAN COMMISSION APPROVES FUZEON, FIRST HIV-FUSION INHIBITOR, FOR USE IN THE FIGHT AGAINST HIV
28-May-03 |
|
|
FUZEON APPROVED FOR MARKETING AND REIMBURSEMENT IN SWITZERLAND
27-May-03 |
|
|
ROCHE FILES NEW VIRACEPT� 625MG FORMULATION WITH EMEA
07-May-03 |
|
|
FUZEON�S ANTIVIRAL ACTIVITY IS MAINTAINED THROUGH 48 WEEKS
28-Apr-03 |
|
|
ROCHE RECEIVES FDA CLEARANCE FOR COBAS AMPLICOR HIV-1 MONITOR TEST
11-Apr-03 |
|
|
FEWER TABLETS AND IMPROVED GI TOLERABILITY OBSERVED WITH VIRACEPT� 625MG COMPARED TO VIRACEPT� 250MG
29-Mar-03 |
|
|
PRELIMINARY 48-WEEK RESULTS SHOW LONGER TERM RESPONSE IN HIV PATIENTS TREATED WITH FUZEON
20-Mar-03 |
|
|
EU CPMP ISSUES POSITIVE OPINION ON FIRST HIV FUSION INHIBITOR, FUZEON
20-Mar-03 |
|
|
U.S. FDA APPROVES FUZEON - FIRST DRUG TO BLOCK ENTRY OF HIV INTO IMMUNE CELLS
17-Mar-03 |
|
|
EUROPEAN PRICE ANNOUNCED FOR AIDS DRUG FUZEON
24-Feb-03 |
|
|
ROCHE ANNOUNCES FIRST RESULTS OF PROMISING NEW PROTEASE INHIBITOR AGAINST RESISTANT HIV
17-Feb-03 |
|
|
ROCHE UPDATES PRICING POLICY FOR PROTEASE INHIBITOR AIDS DRUGS WITHIN ACCELERATING ACCESS INITIATIVE
13-Feb-03 |
